Verrica Pharmaceuticals Inc. (VRCA)

Verrica Pharmaceuticals Inc. (VRCA): revenue, margins and EPS from its SEC filings, and Graham's reads as they come out.

Reads

• Verrica Pharmaceuticals warns of substantial doubt about its ability to continue as a going concern as its cash runway only extends into late 2027. Dodd · VRCA

From its filings

• Quarter ending 2026-09-30: revenue $6.9M (-51.8% vs a year earlier) · operating margin -176.0% · EPS -0.58 · filed 2026-11-13
• Quarter ending 2026-06-30: revenue $5.9M (-53.8% vs a year earlier) · operating margin -223.4% · EPS -0.62 · filed 2026-08-06
• Quarter ending 2026-03-31: revenue $5.0M (+46.1% vs a year earlier) · operating margin -193.4% · EPS -0.45 · filed 2026-05-12
• Quarter ending 2025-12-31: revenue $5.1M (+385.9% vs a year earlier) · operating margin -141.2% · EPS -0.64 · filed 2026-03-11
• Quarter ending 2025-09-30: revenue $14.3M · operating margin 11.3% · EPS -0.03 · filed 2026-11-13
• Quarter ending 2025-06-30: revenue $12.7M · operating margin 11.9% · EPS 0.02 · filed 2026-08-06
• Quarter ending 2025-03-31: revenue $3.4M · operating margin -236.4% · EPS -1.03 · filed 2026-05-12
• Quarter ending 2024-09-30: revenue -$1.8M · operating margin 1162.5% · EPS -4.88 · filed 2025-11-14

Source: SEC EDGAR, 10-Q/10-K, as filed.